This week in drug discovery (20-24 January)
News round-up for 20-24 January by DDW Senior Digital Content Editor Diana Spencer.
In the same week that Phesi revealed that breast cancer is the most studied disease for the fourth year in a row, there have been a number of breakthroughs in the treatment of solid tumours, both in the early preclinical and later clinical stages of research.
The top stories:
Novel approach to cancer extends life by 60% in mouse studies
Results of an in vivo mouse colorectal cancer model study have shown a 60% life extension for Oxford Drug Design’s first-in-class approach against multiple tumours.
CD74 level predicts immunotherapy response in bowel cancer
The amount of a protein called CD74 can indicate which people with bowel cancer may respond best to immunotherapy, new research has revealed.
FDA approved ADC improves breast cancer survival by 37%
The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan-dlnk (Datroway) a Trop-2-directed antibody and topoisomerase inhibitor conjugate, as a treatment for breast cancer.
Breast cancer tops most-studied diseases, study finds
Phesi has released the results of its annual global analysis of all clinical trials conducted in 2024, using data from its AI-driven Trial Accelerator platform.
Bispecific antibody combo for NSCLC could extend life by a year
The European Commission (EC) has approved a Marketing Authorisation (MA) for Lazcluze (lazertinib), in combination with Rybrevant (amivantamab).
